Enfortumab vedotin plus pembrolizumab vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma: 3.5-year follow-up and response analyses from the phase 3 EV-302 study.

Thomas Powles, MD, PhD, FCRP

May 29, 2026, 2:45PM CDT

Abstract & Presentation

Abstract & Presentation

The content displayed at the congress

Abstract Plain Language Summary (aPLS)

Abstract Plain Language Summary (aPLS)

Abstract content summarized in plain language.

These materials are for personal use only and not for reproduction.